I celebrate my ten-year “cancerversary” on January 31st. I can’t believe it’s been 10 years! I will celebrate by spending some intentional time with my family, including my beautiful 16 month-old daughter, Katelyn. My [...]
Barry Hawkins with his sister, Sally Hawkins Barry Hawkins, age 46 Of St. Paul Passed away peacefully August 13, 2016 at home in St. Paul, surrounded by his parents and siblings. Barry [...]
The LRG is proud to welcome Steve Pontell, Esq. who has joined the LRG team as our volunteer attorney. Mr. Pontell is a member of the firm of Verde, Steinberg & Pontell, LLC, established [...]
A recent study from Washington University School of Medicine in St. Louis outlines a novel approach to starving tumor cells that is based on a vulnerable point in cancer cell metabolism. The study was [...]
The recent announcement of the research collaboration between the Life Raft Group and Columbia University Medical Center, NewYork Presbyterian has garnered media attention. Recent articles have been feature in both Cure Today and GenomeWeb. [...]
Jason Sicklick, M.D Recent findings from a population-based retrospective cohort study at the at Moores Cancer Center at UC San Diego Health, led by senior author, Jason Sicklick, M.D., indicate that small [...]
A recent study published in Oncotarget, discussed the potential role of the kinase, ABL1 as a potential impediment to anti-tumor processes in GIST treated with imatinib mesylate. The Life Raft Group’s Research Team member, [...]
New York, NY and Wayne, NJ - January 12, 2017 Columbia University Medical Center, NewYork-Presbyterian and the Life Raft Group (LRG), a patient advocacy organization specializing in GIST cancer, announced today that they have [...]
A recent report from the National Institutes of Health Pediatric and Wildtype GIST Clinic, published in the Journal of Clinical Oncology suggests that surgical resection for wildtype GIST should be restricted to the initial [...]
A recent study published in the Journal of Translational Medicine, presents important research findings for the 10-15% of GIST patients who lack mutations in KIT, PDGFRA, SDHX or RAS pathway indicators, the primary oncogenic [...]
